Massive Top Limited To Take Over Shijiazhuang Pharmaceutical Group
This article was originally published in PharmAsia News
Executive Summary
Legend Holdings' deadline to seek a buyer for its Shijiazhuang Pharmaceutical Group has expired, with Massive Top Limited the only candidate submitting a proposal (PharmAsia News, Nov. 3, 2008). Massive Top is a wholly-owned holding company of Legend Holdings in Hong Kong. Legend Holdings is awaiting approval from the relevant authorities for the equity transfer. Informed sources point out that the move paves the way for Shijiazhuang Pharmaceutical Group's overseas capital operation in the future. (Click here for more - Chinese Language)
You may also be interested in...
Legend Holdings To Sell Shijiazhuang Pharmaceutical Group
Legend Holdings has put on the market its 100 percent stake in Shijiazhuang Pharmaceutical Group to secure RMB 631.5 million, RMB 238.5 million lower than the purchase price of RMB 870 million in June 2007. Legend was supposed to invest RMB 5 billion in Shijiazhuang Pharmaceutical over the next five years and make it a world-class pharmaceutical company. A Legend Holdings executive attributes the move to a restructuring exercise. Analysts note that Legend Holdings lists rigorous criteria for the transfer including to a state-owned enterprise with sustainable support, thus the final potential candidate will likely be a subsidiary of the group with international acquisition and pharmaceutical investment experience. (Click here for more - Chinese Language)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.